Ignite Creation Date:
2025-12-18 @ 8:20 AM
Ignite Modification Date:
2025-12-18 @ 8:20 AM
Study NCT ID:
NCT04640623
Status:
Last Update Posted:
First Post:
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Sponsor:
Organization: